Análisis de periodicidad de reinyección en gonartrosis con distintos tipos de ácidos hialurónicos / Analysis of reinjection periodicity in knee osteoarthritis with different types of hyaluronic acids

Objetivo: Evaluación de la periodicidad de reinyección de ácido hialurónico (AH) en pacientes con gonartrosis. Objetivo secundario: relacionar el grado de artrosis con el tiempo entre infiltraciones y posible estudio por subgrupos entre los diferentes preparados comerciales. Diseño: Estudio observacional retrospectivo. Materiales y método: Revisión de historias clínicas y radiografías de los pacientes con gonartrosis tratados con AH intraarticular en el Servicio de Rehabilitación en el periodo entre enero de 2017 y junio de 2019. Variables: sociodemográficas, lateralidad, fecha del acto, grado de artrosis según Kellgren y Lawrence, AH utilizado, tiempo entre infiltraciones. Análisis estadístico mediante curvas de Kaplan-Meier considerando la reinfiltración como evento final y test de Kruskal Wallis para valores cuantitativos no paramétricos. Resultados: Analizamos 110 actos de infiltración en 67 pacientes: media de edad en momento de infiltración 72,12 años, 85,1% mujeres, 59,1% rodilla derecha. Cuatro tipos de AH: 33 casos al 1%; PM: 0,9 MDa (AH1); 12 al 1,5%; PM: 1,5 – 2 MDa (AH2), 42 al 2%; PM: 1,2 MDa (AH3) y 6 Hilano G-F20; PM: 6 MDa (AH4). En 17 ocasiones no se registró el ácido hialurónico utilizado (AH5). Se reinfiltró en 32 ocasiones (29,09%). Media de meses (Intervalo de Confianza [IC] 95%) entre infiltraciones: AH1 6,9 (5,7-8,16), AH2 12,5 (0- 35), AH3 9,3 (5,5- 13,1), AH4 5 (3 – 6,9). En dos casos en que no se pudo establecer el tipo de preparado infiltrado, el valor medio entre reinfiltraciones fue 8,5 (5,6- 11,4).No hubo resultados estadísticamente significativos al realizar un análisis comparativo el tipo de AH ni el grado de artrosis con el tiempo de reinfiltración. Conclusiones: En nuestro estudio se observa que el AH3 presentó un mayor tiempo entre infiltraciones con respecto a los otros tipos sin poder establecer diferencias significativas.(AU)

Objective: To evaluate the periodicity of hyaluronic acid (HA) reinjection in patients with knee osteoarthritis. Secondary aim: To relate the degree of arthrosis with the time between infiltrations and the possible study by subgroups between the different commercial preparations. Design: Retrospective observational study. Materials and method: Review of medical records and X-rays of patients with knee osteoarthritis that had been treated with intra-articular HA at the Rehabilitation Service in the period between January 2017 and June 2019. Variables: Socio-demographic, Laterality, Intervention Date, Degree of Arthrosis according to Kellgren and Lawrence, HA used, Time between filtrations. Statistical analysis carried out by Kaplan–Meier curves, taking into account the reinfiltration as final event, and Kruskal–Wallis test for non-parametric quantitative data. Results: We analysed 110 infiltration acts in 67 patients: average age at the time of infiltration 72.12 years, 85.1% women, 59.1% right knee. 4 types of HA: 33 cases at 1%. MW: 0.9MDa (HA1), 12 at 1.5%. MW: 1.5–2MDa (HA2), 42 at 2%. MW: 1.2MDa (HA3) and 6 Hylan G-F20. MW: 6MDa (HA4).We reinfiltrated in 31 occasions (28.2%). Average of months (IC 95%) between infiltrations: HA1 6.9 (5.7–8.16), HA2 12.5 (0–35), HA3 9.3 (5.5–13.1), HA4 5 (3–6.9). In 2 cases where it was not possible to establish the type of infiltrated formulations, the mean value between reinfiltrations was 8.5 (5.6–11.4)There were no statistically significant results by relating the HA type or the degree of arthrosis with the reinfiltration time. Conclusions: In our study, we observe that the HA3 presented a longer time between infiltrations in comparison with other types, with no possibility to detect significant differences.(AU)

Fabricación de modelos anatómicos articulares para formación en intervencionismo ecoguiado / Anatomic joint models for eco-guided interventionism training manufacture

Introducción: El intervencionismo ecoguiado ha supuesto un cambio en la forma en que los especialistas de medicina física y rehabilitación se enfrentan al dolor musculoesquelético y a otros problemas como la espasticidad. La implantación de las unidades de intervencionismo ecoguiado mejora los resultados de los tratamientos mínimamente invasivos, habituales en la práctica clínica de nuestra especialidad. El mayor inconveniente de esta práctica es la larga curva de aprendizaje y la dificultad para llevar a cabo prácticas durante los cursos de formación. Objetivo: Desarrollar un sistema de fantomas que permita la práctica de intervencionismo en modelos anatómicos acortando los tiempos de aprendizaje y mejorando la certeza al alcanzar el objetivo de la práctica intervencionista. Métodos: Se describe el método de fabricación de modelos tridimensionales de articulaciones a partir de imágenes obtenidas de tomografía axial computarizada, y su inclusión posterior en moldes realizados con gelatina alimenticia, que permiten obtener unos fantomas similares a modelos articulares reales que posibilitan su estudio mediante técnicas de ecografía y la práctica del intervencionismo ecoguiado. Conclusión: Los modelos articulares tridimensionales con gelatina alimenticia son útiles en la práctica y aprendizaje de las técnicas de intervencionismo ecoguiado articular.(AU)

Introduction: Eco-guided interventionism has changed the way Physical Medicine and Rehabilitation specialists deal with musculoskeletal pain and other problems such as spasticity. The implementation of the Eco-Guided Intervention Units improves the results of the usual minimally invasive treatments in our speciality's clinical practice. The biggest drawback of this practice is the long learning curve and the difficulty of practice during training courses. Objective: To develop a system of phantoms that allow the practice of interventionism in anatomical models by shortening learning times and improving certainty by achieving the objective of interventionist practice. Methods: Describes the method of manufacturing three-dimensional models of joints with images obtained from computerized axial tomography, and their subsequent inclusion in gelatin's made molds, which allow to obtain phantoms, similar to real joint models, that allow to study using ultrasound techniques, and the practice of eco-guided interventionism. Conclusion: Three-dimensional joint models made with gelatin are useful in the practice and learning of joint eco-guided interventionism techniques.(AU)

[Anatomic joint models for eco-guided interventionism training manufacture]. / Fabricación de modelos anatómicos articulares para formación en intervencionismo ecoguiado.

INTRODUCTION: Eco-guided interventionism has changed the way Physical Medicine and Rehabilitation specialists deal with musculoskeletal pain and other problems such as spasticity. The implementation of the Eco-Guided Intervention Units improves the results of the usual minimally invasive treatments in our speciality's clinical practice. The biggest drawback of this practice is the long learning curve and the difficulty of practice during training courses. OBJECTIVE: To develop a system of phantoms that allow the practice of interventionism in anatomical models by shortening learning times and improving certainty by achieving the objective of interventionist practice. METHODS: Describes the method of manufacturing three-dimensional models of joints with images obtained from computerized axial tomography, and their subsequent inclusion in gelatin's made molds, which allow to obtain phantoms, similar to real joint models, that allow to study using ultrasound techniques, and the practice of eco-guided interventionism. CONCLUSION: Three-dimensional joint models made with gelatin are useful in the practice and learning of joint eco-guided interventionism techniques.

[Analysis of reinjection periodicity in knee osteoarthritis with different types of hyaluronic acids]. / Análisis de periodicidad de reinyección en gonartrosis con distintos tipos de ácidos hialurónicos.

OBJECTIVE: To evaluate the periodicity of hyaluronic acid (HA) reinjection in patients with knee osteoarthritis. Secondary aim: To relate the degree of arthrosis with the time between infiltrations and the possible study by subgroups between the different commercial preparations. DESIGN: Retrospective observational study. MATERIALS AND METHOD: Review of medical records and X-rays of patients with knee osteoarthritis that had been treated with intra-articular HA at the Rehabilitation Service in the period between January 2017 and June 2019. VARIABLES: Socio-demographic, Laterality, Intervention Date, Degree of Arthrosis according to Kellgren and Lawrence, HA used, Time between filtrations. Statistical analysis carried out by Kaplan-Meier curves, taking into account the reinfiltration as final event, and Kruskal-Wallis test for non-parametric quantitative data. RESULTS: We analysed 110 infiltration acts in 67 patients: average age at the time of infiltration 72.12 years, 85.1% women, 59.1% right knee. 4 types of HA: 33 cases at 1%. MW: 0.9MDa (HA1), 12 at 1.5%. MW: 1.5-2MDa (HA2), 42 at 2%. MW: 1.2MDa (HA3) and 6 Hylan G-F20. MW: 6MDa (HA4). We reinfiltrated in 31 occasions (28.2%). Average of months (IC 95%) between infiltrations: HA1 6.9 (5.7-8.16), HA2 12.5 (0-35), HA3 9.3 (5.5-13.1), HA4 5 (3-6.9). In 2 cases where it was not possible to establish the type of infiltrated formulations, the mean value between reinfiltrations was 8.5 (5.6-11.4) There were no statistically significant results by relating the HA type or the degree of arthrosis with the reinfiltration time. CONCLUSIONS: In our study, we observe that the HA3 presented a longer time between infiltrations in comparison with other types, with no possibility to detect significant differences.

Análisis descriptivo de coste de tratamiento de la espasticidad con diferentes tipos de toxina botulínica A, a lo largo de un año / Descriptive analysis of the annual cost of treating spasticity with different types of botulinum toxin A

Introducción: La toxina botulínica A es el tratamiento de elección para la espasticidad localizada. Sin embargo, no se tiene un conocimiento real de su repercusión económica.El objetivo de este trabajo es describir los costes reales del tratamiento de la espasticidad en adultos con toxina botulínica A en una consulta de espasticidad de un Servicio de Rehabilitación, a lo largo de un año.MétodosSe ha realizado la revisión retrospectiva de todos los actos médicos llevados a cabo a lo largo del año 2017. Se han recogido el tipo de toxina utilizado (incobotulinumtoxin A, onabotulinumtoxin A, abobotulinumtoxin A), las unidades inyectadas, la región anatómica y el tiempo transcurrido entre infiltraciones. Se han obtenido los costes de la medicación y los costes indirectos, como los de personal o los fungibles.ResultadosEste es el primer trabajo que describe los costes reales del tratamiento de la espasticidad en adultos con toxina botulínica A en España. En 2017 se realizaron 510 actos de infiltración en 164 pacientes. El coste total de tratamiento de espasticidad en nuestro servicio fue de 116.789,70 €. El coste medio anual por paciente fue 603,64 € para onabotulinumtoxin A, de 642,69 € para abobotulinumtoxin A y de 707,59 € para incobotulinumtoxin A.ConclusionesNuestro estudio económico de actividad clínica real sigue una pauta similar a la descrita en los modelos teóricos publicados en la literatura. Las diferentes características de cada toxina y la imposibilidad de establecer una equivalencia entre las unidades de cada una de ellas impiden la comparación directa de estos costes. (AU)

Introduction: Botulinum toxin A is the first-line treatment for localised spasticity. However, the economic impact of this treatment is not fully known.This study aimed to describe the real costs of botulinum toxin A for the treatment of adult patients with spasticity at a spasticity clinic pertaining to a rehabilitation service, over a period of one year.MethodsWe retrospectively reviewed all medical procedures carried out during the year 2017. We collected data on the type of toxin used (incobotulinumtoxin A, onabotulinumtoxin A, or AAbobotulinumtoxin A), the number of units injected, the anatomical region, and the time elapsed between infiltrations. The costs of medication and indirect costs, such as staff and consumables, were also calculated.ResultsThis is the first study to describe the real costs of botulinum toxin treatment of spasticity in adult patients in Spain. In 2017, 510 infiltration procedures were performed in 164 patients. The total cost of treating spasticity in our service was €116 789.70. The mean annual cost per patient was €603.64 for onabotulinumtoxin A, €642.69 for abobotulinumtoxin A, and €707.59 for incobotulinumtoxin A.ConclusionsOur economic study of real clinical practice is consistent with the theoretical models published in the literature. The different characteristics of each toxin and the inability to establish an equivalence between the units of each drug prevents us from directly comparing these costs. (AU)

Descriptive analysis of the annual cost of treating spasticity with different types of botulinum toxin A.

INTRODUCTION: Botulinum toxin A is the first-line treatment for localised spasticity. However, the economic impact of this treatment is not fully known. This study aimed to describe the real costs of botulinum toxin A for the treatment of adult patients with spasticity at a spasticity clinic pertaining to a rehabilitation service, over a period of one year. METHODS: We retrospectively reviewed all medical procedures carried out during the year 2017. We collected data on the type of toxin used (incobotulinumtoxin A, onabotulinumtoxin A, or Abobotulinumtoxin A), the number of units injected, the anatomical region, and the time elapsed between infiltrations. The costs of medication and indirect costs, such as staff and consumables, were also calculated. RESULTS: This is the first study to describe the real costs of botulinum toxin treatment of spasticity in adult patients in Spain. In 2017, 510 infiltration procedures were performed in 164 patients. The total cost of treating spasticity in our service was 116 789.70. The mean annual cost per patient was 603.64 for onabotulinumtoxin A, 642.69 for abobotulinumtoxin A, and 707.59 for incobotulinumtoxin A. CONCLUSIONS: Our economic study of real clinical practice is consistent with the theoretical models published in the literature. The different characteristics of each toxin and the inability to establish an equivalence between the units of each drug prevents us from directly comparing these costs.

Descriptive analysis of the annual cost of treating spasticity with different types of botulinum toxin A. / Análisis descriptivo de coste de tratamiento de la espasticidad con diferentes tipos de toxina botulínica A, a lo largo de un año.

INTRODUCTION: Botulinum toxin A is the first-line treatment for localised spasticity. However, the economic impact of this treatment is not fully known. This study aimed to describe the real costs of botulinum toxin A for the treatment of adult patients with spasticity at a spasticity clinic pertaining to a rehabilitation service, over a period of one year. METHODS: We retrospectively reviewed all medical procedures carried out during the year 2017. We collected data on the type of toxin used (incobotulinumtoxin A, onabotulinumtoxin A, or AAbobotulinumtoxin A), the number of units injected, the anatomical region, and the time elapsed between infiltrations. The costs of medication and indirect costs, such as staff and consumables, were also calculated. RESULTS: This is the first study to describe the real costs of botulinum toxin treatment of spasticity in adult patients in Spain. In 2017, 510 infiltration procedures were performed in 164 patients. The total cost of treating spasticity in our service was €116 789.70. The mean annual cost per patient was €603.64 for onabotulinumtoxin A, €642.69 for abobotulinumtoxin A, and €707.59 for incobotulinumtoxin A. CONCLUSIONS: Our economic study of real clinical practice is consistent with the theoretical models published in the literature. The different characteristics of each toxin and the inability to establish an equivalence between the units of each drug prevents us from directly comparing these costs.

Cost of peripheral facial palsy treatment with Botulinum Toxin type A.

INTRODUCTION: Facial palsy (FP) is one of the most common neuropathies. Overall, 15%-30% of patients develop chronic sequelae. Several studies support the use of botulinum toxin A (BoNT-A) in the treatment of FP sequelae. No studies have analyzed the cost of treating FP with BoNT-A. METHODS: A retrospective review of data from all clinical records of consultations and procedures that took place at the FP Treatment Unit clinic throughout 2017. Type of BoNT-A used, total dose used, unilateral or bilateral injection, date of consultation, and gender were collected. The price of expendable materials, BoNT-A, and the 2017 salary scale was obtained to establish costs. RESULTS: During 2017, 605 clinical procedures were conducted in 240 patients. The mean number of procedures was 2.5 (0.80). The average time between procedures was 124(28.72) days. The total annual cost was 34.155,10€. The average annual cost of BoNT-A for each procedure was 39,93€, and the total annual cost of BoNT-A was 24.160,58€. On average, more units of IncotoxA were injected. This difference is not reflected in the final cost of each BoNT-A. For patients who achieved treatment stability, the average annual cost per patient was 106,6€ (OnatoxA) and 100,6€ (IncotoxA). CONCLUSION: In our unit, treatment with BoNT-A in FP sequelae had an average annual cost of 124,31€ per patient, requiring a visit to the hospital to receive treatment every 124 days. Given the functional and quality of life improvements, we should consider that it is a beneficial treatment at an acceptable cost.

La elección de plazas de médico interno residente de Medicina Física y Rehabilitación / Resident physicians' choice of Physical and Rehabilitation Medicine

No disponible

Estudio de la población atendida en una urgencia específica de rehabilitación / Study of the population attended in a rehabilitation especific emergency

Introducción: El objetivo de este estudio ha sido valorar las patologías y las características demográficas de la población atendida en la urgencia del Servicio de Rehabilitación del Hospital de Rehabilitación y Traumatología (HRT) del Hospital Universitario La Paz de Madrid. Los facultativos de este Servicio atienden a los pacientes que acuden a urgencias y que no han sufrido traumatismo previo.Pacientes y métodos: De manera aleatoria se eligió un mes del año (noviembre 1999) y se procedió a la revisión de todas las historias clínicas de pacientes evaluados en urgencias por médicos rehabilitadores. En total sumaron 1.284 registros. De ellos se recogieron datos administrativos (fecha, hora de asistencia,...), demográficos (edad, sexo) y de asistencia médica (diagnóstico). Para el manejo de los datos se utilizaron los programas Ms Excel 97® y SAS®.Resultados: De los 1.284 pacientes (un 5 por ciento del total de urgencias del centro), un 62 por ciento eran mujeres. La mediana de edad fue de 42 años, con un rango desde 95 hasta tres años. La mayor parte de la población se incluía dentro del grupo de 25-45 años de edad (26,5 por ciento). Los días más frecuentados fueron lunes (18,5 por ciento), martes (15,5 por ciento) y domingos (14,8 por ciento), con una media diaria de asistencia de 42,8 pacientes/día (rango 26 hasta 57). Las patologías más frecuentemente atendidas fueron las relativas a columna dorsolumbar (25 por ciento), cervical (15,7 por ciento), rodilla (12,6 por ciento), hombro (8,2 por ciento) y muñeca (7,5 por ciento). En cuanto al tiempo de evolución, el 41 por ciento acudía a urgencias en los tres primeros días de dolor, mientras que un 13,6 por ciento presentaba sintomatología de más de un mes de evolución al acudir a urgencias. Las horas de mayor afluencia coinciden con aquellas en que los ambulatorios y centros de atención primaria mantienen actividad asistencial, incluso de urgencias de área (9 a 19 horas).Conclusión: Los dolores osteomusculares sin claro origen traumático suponen una importante carga asistencial de las urgencias de un gran hospital. Con gran frecuencia los pacientes prefieren acudir a la urgencia del hospital como primera visita en vez de a las consultas de los centros de atención primaria o a las urgencias de área. La educación sanitaria debería ser fundamental para solucionar esta sobrecarga asistencial (AU)